SciELO - Scientific Electronic Library Online

SciELO - Scientific Electronic Library Online

Referencias del artículo

GHOLAMI, Kheirollah; KAMALI, Elahe; HAJIABDOLBAGHI, Mahboubeh  y  SHALVIRI, Gloria. Evaluación de las reacciones adversas de los antituberculosos en pacientes hospitalizados. Pharmacy Pract (Granada) [online]. 2006, vol.4, n.3, pp.134-138. ISSN 1885-642X.

    1. World Health Organization. Global Tuberculosis Control. WHO report 2001. Geneva, Switzerland: WHO/CDS/TB; 2001. 287. [ Links ]

    2. Kopanoff DE, Snider DE, Caras GJ. Isoniazid-related hepatitis. Am Rev Respir Dis 1978:117:991-1001. [ Links ]

    3. Burman WJ. Reves RR.. Hepatotoxicity from Rifampin plus Pyrazinamide. Lessons for Policymakers and Messages for Care Providers. Am J Respir Crit Care Med 2001; 164: 1112-3. [ Links ]

    4. British Thoracic and Tuberculosis Association: Short course chemotherapy in pulmonary tuberculosis. Lancet 1975; 119-24. [ Links ]

    5. Tanaja DP, Kaur D. Study on hepatotoxicity and other side effects of antituberculosis drugs. J Indian Med Assoc 1990; 88:278-80. [ Links ]

    6. Snider DE, Long MW, Cross FS, Farer LS. Six months Isoniazid and Rifampin therapy for pulmonary tuberculosis: report of a United States Public Health Service cooperative trial. Am Rev Respir Dis 1984; 77:233-42. [ Links ]

    7. Sharma SK., Balamurgan A., Saha PK., Pandey RM. Mehra NK. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during Antituberculosis treatment. Am J Respir Crit Care Med. 2002;166:916-9. [ Links ]

    8. World Health Organization. Uppsala Monitoring Center. Safety monitoring of medicinal products, guidelines for setting up and running pharmacovigilance center, Geneva, 1996. [ Links ]

    9. Naranjo CA., Busto U., Sellers EM. A method for estimating the probability of Adverse Drug Reactions. Clin Pharmacother 1981; 30:239-45. [ Links ]

    10. Hartwig SC., Siegel J., Schneider PJ. Preventability and severity assessment in reporting Adverse Drug Reactions. Am J Hosp Pharm, 1992; 49:2229-32. [ Links ]

    11. Schumock GT, Thornton JP. Focusing on the preventability of Adverse Drug Reactions. Hosp Pharm. 1992; 27:538. [ Links ]

    12. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of Serious Side Effects from First-Line Antituberculosis Drugs among Patients Treated for Active Tuberculosis. Am J Resp Crit Care Med. 2003. 167: 1472-7. [ Links ]

    13. Gholami K., Shalviri G. Factors associated with preventability, predictability and severity of ADRs. Ann Pharmacother 1999; 33:236-40. [ Links ]

    14. Gholami K, Parsa S, Shalviri G, Sharifzadeh M, Assasi N. Anti-infectives-induced adverse drug reactions in hospitalized patients. Pharmacoepidemiol Drug Safe 2005; 14:501-6. [ Links ]

    15. Kays MB. Tuberculosis. In: Koda-Kimble MA, Young LY, Kradijan WA, Guglielmo JB, Allfredge BK, Corelli RL. Applied Therapeutics, The Clinical Use of Drugs. Eighth Edition 2005. Lippincott Williams and Wilkins. p.71-83. [ Links ]